Anti-SARS-Cov-2 antibodies derived from CR3022
US11034762B1 · kind B1 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2020 |
| Grant date | Jun 15, 2021 |
| Priority date | — |
| Expiry date | May 14, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/165
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides antibodies that are derived from CFR3022 and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS CoV 2 infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.